Neurocrine Biosciences (NBIX) Prepaid Assets (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Prepaid Assets for 17 consecutive years, with $217.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Prepaid Assets rose 79.87% year-over-year to $217.1 million; the trailing twelve-month figure through Jun 2026 stood at $217.1 million (up 79.87% YoY), and the FY2025 full-year result was $170.7 million, up 168.4% from the prior year.
• Prepaid Assets fell to $217.1 million in Q2 2026 per NBIX's latest filing, from $224.8 million in the prior quarter.
• Across five years, Prepaid Assets topped out at $224.8 million in Q1 2026 and bottomed at $60.8 million in Q1 2022.
• Historically, Prepaid Assets has averaged $118.2 million across 5 years, with a median of $110.7 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Prepaid Assets plunged 34.97% in 2024, then soared 168.4% in 2025.
• Over 5 years, Prepaid Assets stood at $79.1 million in 2022, then advanced by 23.64% to $97.8 million in 2023, then slumped by 34.97% to $63.6 million in 2024, then surged by 168.4% to $170.7 million in 2025, then advanced by 27.18% to $217.1 million in 2026.
• According to Business Quant data, Prepaid Assets over the past three periods registered $217.1 million, $224.8 million, and $170.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.